MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Synucleinopathies"

  • 2019 International Congress

    Premature State of Oligodendrocytes Potentially Provides Critical Period for Extracellular Pathological α-Synuclein to Invade Oligodendrocyte Lineage Cells

    S. Kaji, T. Maki, T. Ayaki, R. Takahashi (Kyoto, Japan)

    Objective: Multiple system atrophy (MSA) is pathologically characterized by accumulation of misfolded α-synuclein (α-syn) in oligodendrocytes (OLGs), which is known as glial cytoplasmic inclusions (GCIs).…
  • 2019 International Congress

    Automated Interpretation of FP-CIT-SPECT images based on Artificial Intelligence

    M. Meier, J. Hammes, A. Drzezga, T. Dratsch, C. Kobe, D. Dos Santos, T. van Eimeren (Cologne, Germany)

    Objective: Our objective is to develop an AI-based approach to automatically rate FIP-CIT-SPECT data. Background: FP-CIT-SPECT visualizes the integrity of nigro-striatal dopaminergic synapses in vivo.…
  • 2018 International Congress

    Prevalence of REM Sleep Behavior Disorder in Sun City, Arizona

    D. Shprecher, A. Intorcia, M. Glass, J. Curry, J. Walker, B. Cutler, M. Callan, G. Serrano, N. Zhang, L. Sue, K. Davis, T. Beach (Sun City, AZ, USA)

    Objective: Determine prevalence of REM Sleep Behavior Disorder (RBD) in Sun City, Arizona Background: RBD is the strongest known clinical risk factor for neurodegenerative disorders…
  • 2018 International Congress

    Predicting Alpha-Synuclein Pathology by REM Sleep Behavior Disorder Diagnosis

    D. Shprecher, C. Adler, N. Zhang, J. Hentz, G. Serrano, B. Dugger, H. Shill, R. Savica, J. Caviness, M. Sabbagh, C. Belden, E. Driver-Dunckley, S. Mehta, L. Sue, K. Davis, E. Zamrini, T. Beach (Sun City, AZ, USA)

    Objective: Determine sensitivity, specificity and predictive value of clinician diagnosed probable REM sleep behavior disorder (PRBD) in predicting alpha-synuclein pathology. Background: Inability to accurately diagnose…
  • 2018 International Congress

    Longitudinal alpha-synuclein in cerebrospinal fluid in early Parkinson’s disease, prodromal PD and healthy controls

    B. Mollenhauer, C. Caspell-Garcia, C. Coffey, P. Taylor, A. Singleton, L. Shaw, J. Trojanowski, M. Frasier, T. Simuni, A. Siderowf, K. Marek, D. Galasko (Kassel, Germany)

    Objective: To examine the longitudinal relationships between total alpha-synuclein (aSyn) changes in cerebrospinal fluid (CSF), clinical measures, and factors that may influence CSF aSyn in…
  • 2018 International Congress

    PROMESA: A randomised, double-blind, placebo-controlled trial to evaluate the progression rate of MSA under EGCG supplementation as anti-aggregation-approach

    J. Levin, S. Maass, M. Schuberth, A. Giese, W. Oertel, W. Poewe, C. Trenkwalder, G. Wenning, U. Mansmann, M. Suedmeyer, K. Eggert, B. Mollenhauer, A. Lipp, M. Loehle, J. Classen, A. Muenchau, J. Kassubeck, G. Ebersbach, D. Berg, S. Egert, C. Eberhardt, F. Paul, K. Boetzel, B. Ertl-Wagner, H. Huppertz, I. Ricard, G. Hoeglinger (Munich, Germany)

    Objective: To evaluate the safety and tolerability of epigallocatechin gallate (EGCG) in high doses and its efficacy to slow down disease progression in patients with…
  • 2018 International Congress

    Incidence, prevalence and clinical features of sleep disorders in alphasynucleinopthies: A cohort study

    C. Borrue-Fernandez, J. Fernandez- Cuesta, MJ. Abenza Abildua (San Sebastian Reyes, Spain)

    Objective: Analyze the sleep disorders incidence, prevelence an clinical features depending on the time of evolution, depending on the type of alpha-synuclein, and the subtype…
  • 2018 International Congress

    Free-living gait in REM sleep behaviour disorder: Measures of prodromal Parkinson’s disease?

    S. Del Din, T. Barber, C. Lo, M. Rolinski, F. Baig, M. Hu, L. Rochester (Newcastle upon Tyne, United Kingdom)

    Objective: The aim of this study was to investigate if free-living gait monitoring can discriminate individuals with REM sleep behaviour disorder (RBD) from controls. Background:…
  • 2018 International Congress

    Early synaptic loss and synaptic instability in a mouse model of prodromal Parkinson’s disease

    Y. Hatanaka, R. Takahashi (Kyoto, Japan)

    Objective: In order to elucidate very early pathologis of Parkinson’s disease (PD), we focused on synaptic pathologies in a newly developed mouse model of prodromal…
  • 2018 International Congress

    A founder French-Canadian GBA mutation, p.W378G, as a cause for synucleinopathies and Gaucher disease

    Z. Gan-Or, J. Ruskey, S. Zhou, L. Roncière, A. Alam, D. Spiegelman, J. Trempe, R. Postuma, N. Dupre, D. Amato (Montreal, QC, Canada)

    Objective: To examine and characterize founder GBA mutations in the French-Canadian (FC) population Background: GBA mutations are the most common genetic risk factors for Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 17
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley